Puma Biotechnology earnings were $38.1M for the trailing 12 months ending Mar 31, 2025, with 133.3% growth year over year. The latest PBYI earnings report on Mar 31, 2025 announced Q1 2025 earnings of $3.0M, down 84.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PBYI reported annual earnings of $30.3M, with 40.2% growth.
PBYI past earnings growth
How has PBYI's earnings growth performed historically?
What were Puma Biotechnology's earnings last quarter?
On PBYI's earnings call on Invalid Date, Puma Biotechnology (NASDAQ: PBYI) reported Q1 2025 earnings per share (EPS) of $0.06, up 160% year over year. Total PBYI earnings for the quarter were $2.97 million. In the same quarter last year, Puma Biotechnology's earnings per share (EPS) was -$0.10.
As of the last Puma Biotechnology earnings report, Puma Biotechnology is currently profitable. Puma Biotechnology's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $38.07 million, a 147.59% increase year over year.
What was PBYI's earnings growth in the past year?
As of Puma Biotechnology's earnings date in Invalid Date, Puma Biotechnology's earnings has grown 133.33% year over year. This is 121.8 percentage points higher than the US Biotechnology industry earnings growth rate of 11.53%. PBYI earnings in the past year totalled $38.07 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.